Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.20 USD
+0.05 (1.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.20 USD
+0.05 (1.59%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $3.20 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Zacks News
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Repare Therapeutics Inc. (RPTX) Soars 8.8%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Biogen (BIIB) to Stop Selling Alzheimer's Disease Drug Aduhelm
by Zacks Equity Research
Biogen (BIIB) aims to build a leading Alzheimer's disease franchise with the new drug Leqembi. The company quits commercializing the controversial Alzheimer's disease drug, Aduhelm.
Repare Therapeutics (RPTX) Rises 34% in a Week: Here's Why
by Zacks Equity Research
Repare Therapeutics (RPTX) rises 34% in a week after announcing plans to begin clinal-stage development of two additional candidates, RP-1664 and RP-3467, in 2024 in several solid tumor indications.
Down -25.05% in 4 Weeks, Here's Why Repare Therapeutics Inc. (RPTX) Looks Ripe for a Turnaround
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Repare Therapeutics Inc. (RPTX) is Poised for a Turnaround After Losing -26.14% in 4 Weeks
by Zacks Equity Research
The heavy selling pressure might have exhausted for Repare Therapeutics Inc. (RPTX) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Strength Seen in Repare Therapeutics Inc. (RPTX): Can Its 12.2% Jump Turn into More Strength?
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 66.27% and 315.79%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Aadi Bioscience, Inc. (AADI) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Aadi Bioscience, Inc. (AADI) delivered earnings and revenue surprises of -4.69% and 0.31%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 1.19% and 19.46%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
MannKind (MNKD) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
MannKind (MNKD) delivered earnings and revenue surprises of 20% and 8.68%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
How Much Upside is Left in Repare Therapeutics Inc. (RPTX)? Wall Street Analysts Think 214.72%
by Zacks Equity Research
The mean of analysts' price targets for Repare Therapeutics Inc. (RPTX) points to a 214.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Repare Therapeutics Inc. (RPTX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of -2.74% and 84.75%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength?
by Zacks Equity Research
Tarsus Pharmaceuticals, Inc. (TARS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Repare Therapeutics Inc. (RPTX) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
After losing some value lately, a hammer chart pattern has been formed for Repare Therapeutics Inc. (RPTX), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.
Ultragenyx (RARE) Posts Preliminary '22 Results, Gives '23 View
by Zacks Equity Research
Ultragenyx (RARE) reports preliminary product revenues for its marketed drugs, Crysvita, Mepsevii and Dojolvi for the full year 2022. The company issues product revenue guidance for 2023.
Alnylam (ALNY) Posts Strong Preliminary Revenues for 4Q & FY22
by Zacks Equity Research
Alnylam (ALNY) reports strong preliminary product revenues for its marketed drugs, Onpattro, Amvuttra, Givlaari and Oxlumo for the fourth quarter and full year of 2022.
Roche's (RHHBY) Cancer Drug Glofitamab Gets FDA Priority Review
by Zacks Equity Research
The FDA accepts and grants priority review to Roche's (RHHBY) biologics license application for glofitamab to treat relapsed or refractory large B-cell lymphoma. The decision is due on Jul 1, 2023.
Geron (GERN) Up on Imetelstat Data on Myelodysplastic Syndromes
by Zacks Equity Research
Geron (GERN) posts positive top-line data from the phase III IMerge study investigating its lead candidate, imetelstat for treating lower risk myelodysplastic syndromes. Shares up.
AstraZeneca's (AZN) Imfinzi+Imjudo Gets Japan Nod for 2 Cancers
by Zacks Equity Research
The Japanese Ministry of Health approves AstraZeneca's (AZN) Imfinzi plus Imjudo for treating advanced liver cancer and lung cancer.
Syndax's (SNDX) Leukemia Drug Gets FDA Breakthrough Therapy Tag
by Zacks Equity Research
The FDA bestows a Breakthrough Therapy designation to Syndax's (SNDX) revumenib for treating patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement. Stock up.
Oncolytics (ONCY) Up on Lead Drug Securing 2nd FDA Fast Track Tag
by Zacks Equity Research
Oncolytics Biotech (ONCY) receives a fast-track designation from the FDA for pelareorep combined with Roche's Tecentriq in advanced/metastatic pancreatic cancer indication.
Valneva (VALN) Up on 6-Month Lyme Disease Jab Persistence Data
by Zacks Equity Research
Persistence data from a mid-stage study showed that Valneva's (VALN) Lyme disease vaccine elicited antibody levels which remained above baseline six months after completing dose administration in children and adults.
Repare Therapeutics Inc. (RPTX) Just Overtook the 20-Day Moving Average
by Zacks Equity Research
Is it a good or bad thing when a stock surpasses resistance at the 20-day simple moving average?
bluebird (BLUE) to Boost Cash With Priority Review Voucher Sale
by Zacks Equity Research
bluebird (BLUE) is set to sell one of its two priority review vouchers. This will strengthen its financial position as its existing cash balance is expected to exhaust by second-quarter 2023.